Physician profile
B Grabois
NPI 1730167743
$4,315.80
in general payments reported to CMS, 2019-2025
35 companies · $715 in 2025
The $715 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $233 · 2021: $1,062 · 2022: $423 · 2023: $607 · 2024: $582 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,903.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $914.07 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $416.53 | 2019-2025 | |
| Hologic Sales and Service, LLC | $340.73 | 2019-2025 | Novasure, Myosure Tissue Removal Device, Aptima |
| Gynesonics, INC. | $338.41 | 2021 | |
| Allergan, INC. | $309.07 | 2019-2020 | |
| Astellas Pharma US INC | $275.30 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $253.62 | 2021-2025 | |
| Exact Sciences Corporation | $207.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $186.46 | 2023-2024 | Accrufer |
| Coopersurgical, INC. | $142.83 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Evofem Biosciences, INC. | $100.80 | 2024-2025 | Phexxi, Solosec, Phexx |
| Organon LLC | $93.69 | 2021-2024 | Nexplanon |
| Therapeuticsmd, INC. | $91.13 | 2020-2022 | |
| Pfizer INC. | $56.44 | 2023-2025 | |
| Dysis Medical, INC. | $55.29 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $55.02 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $48.85 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $45.20 | 2019 | |
| Duchesnay USA Incorporated | $40.79 | 2019 | |
| Radius Health, INC. | $37.25 | 2020-2021 | |
| Millicent US INC | $35.48 | 2021-2025 | Intrarosa |
| Amgen INC. | $34.18 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $31.24 | 2023 | Myfembree |
| Vanda Pharmaceuticals INC. | $29.35 | 2023 | Hetlioz, Fanapt |
| Bausch Health US, LLC | $22.82 | 2022 | |
| Vertical Pharmaceuticals, LLC | $22.31 | 2019 | |
| Daiichi Sankyo INC. | $19.59 | 2020 | |
| Ascend Therapeutics US, LLC | $19.10 | 2024 | |
| Scynexis, INC. | $19.09 | 2022 | |
| Lupin INC. | $16.43 | 2021 | |
| Amag Pharmaceuticals, INC. | $15.69 | 2019 | |
| Mission Pharmacal Company | $15.11 | 2021 | |
| Alkermes, INC. | $13.77 | 2022 | |
| Zyla Life Sciences, INC. | $12.26 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw B Grabois listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.